Inflammatory biomarkers in Alzheimer's disease plasma. Issue 6 (29th April 2019)

• Record Type: Journal Article
• Authors: Morgan, Angharad R.; Touchard, Samuel; Leckey, Claire; O'Hagan, Caroline; Nevado‐Holgado, Alejo J.; Barkhof, Frederik; Bertram, Lars; Blin, Olivier; Bos, Isabelle; Dobricic, Valerija; Engelborghs, Sebastiaan; Frisoni, Giovanni; Frölich, Lutz; Gabel, Silvey; Johannsen, Peter; Kettunen, Petronella; Kłoszewska, Iwona; Legido‐Quigley, Cristina; Lleó, Alberto; Martinez‐Lage, Pablo; Mecocci, Patrizia; Meersmans, Karen; Molinuevo, José Luis; Peyratout, Gwendoline; Popp, Julius; Richardson, Jill; Sala, Isabel; Scheltens, Philip; Streffer, Johannes; Soininen, Hikka; Tainta‐Cuezva, Mikel; Teunissen, Charlotte; Tsolaki, Magda; Vandenberghe, Rik; Visser, Pieter Jelle; Vos, Stephanie; Wahlund, Lars‐Olof; Wallin, Anders; Westwood, Sarah; Zetterberg, Henrik; Lovestone, Simon; Morgan, B. Paul;
• Is Part Of: Alzheimer's & dementia. Volume 15:Issue 6(2019)
• Page Start: 776
• Page End: 787
• Publication Date: 2019-04-29
• Subjects: Alzheimer's disease -- Biomarker -- Plasma -- Inflammation -- Complement; Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1016/j.jalz.2019.03.007
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Introduction: Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a "Holy Grail" of AD research and intensively sought; however, there are no well‐established plasma markers. Methods: A hypothesis‐led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed. Results: Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP‐1, eotaxin‐1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP‐1, eotaxin‐1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71). Discussion: Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.